Merck & Co withdraws vorinostat EU filing for cutaneous T-cell lymphoma
This article was originally published in Scrip
Executive Summary
Merck Sharp & Dohme has withdrawn an application to market Vorinostat MSD (vorinostat) in the EU for the treatment of advanced-stage cutaneous T-cell lymphoma (CTCL) patients who have failed prior therapies after the CHMP said that the data provided were not sufficient to allow it to conclude a positive benefit-risk balance for the treatment.